Personalis (NASDAQ:PSNL) Shares Gap Up – Here’s Why

Personalis, Inc. (NASDAQ:PSNL) shares gapped up before the market opened on Monday . The stock had previously closed at $6.93, but opened at $7.64. Personalis shares last traded at $8.9690, with a volume of 1,780,355 shares trading hands.

Analysts Set New Price Targets

PSNL has been the topic of a number of research analyst reports. Needham & Company LLC boosted their price target on shares of Personalis from $7.00 to $10.00 and gave the company a “buy” rating in a research note on Wednesday, November 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Personalis in a report on Wednesday, October 8th. Lake Street Capital reissued a “buy” rating and issued a $11.00 target price on shares of Personalis in a research report on Wednesday. Wall Street Zen upgraded Personalis from a “sell” rating to a “hold” rating in a research report on Saturday, September 20th. Finally, BTIG Research lifted their price objective on Personalis from $6.00 to $11.00 and gave the company a “buy” rating in a research note on Wednesday, October 22nd. Six analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $9.33.

Personalis Stock Performance

The company has a market cap of $770.96 million, a PE ratio of -9.88 and a beta of 1.92. The company’s 50-day simple moving average is $7.33 and its 200 day simple moving average is $6.09.

Personalis (NASDAQ:PSNL) last announced its quarterly earnings data on Tuesday, November 4th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28) by $0.04. Personalis had a negative return on equity of 38.25% and a negative net margin of 106.92%.The business had revenue of $14.50 million during the quarter, compared to analysts’ expectations of $13.31 million. Personalis has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Analysts forecast that Personalis, Inc. will post -1.4 EPS for the current year.

Insider Activity

In other news, CEO Christopher M. Hall sold 29,612 shares of the business’s stock in a transaction dated Monday, November 3rd. The stock was sold at an average price of $8.99, for a total value of $266,211.88. Following the completion of the sale, the chief executive officer directly owned 148,486 shares of the company’s stock, valued at approximately $1,334,889.14. The trade was a 16.63% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 3.80% of the company’s stock.

Hedge Funds Weigh In On Personalis

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Aberdeen Group plc raised its stake in shares of Personalis by 472.3% during the first quarter. Aberdeen Group plc now owns 1,704,784 shares of the company’s stock worth $5,984,000 after purchasing an additional 1,406,895 shares during the last quarter. Geode Capital Management LLC increased its stake in Personalis by 165.6% in the 2nd quarter. Geode Capital Management LLC now owns 1,365,598 shares of the company’s stock valued at $8,960,000 after buying an additional 851,422 shares during the period. Blue Water Life Science Advisors LP raised its position in Personalis by 42.6% during the 2nd quarter. Blue Water Life Science Advisors LP now owns 1,676,300 shares of the company’s stock worth $10,997,000 after buying an additional 500,900 shares during the last quarter. ARK Investment Management LLC raised its position in Personalis by 6.1% during the 1st quarter. ARK Investment Management LLC now owns 7,188,197 shares of the company’s stock worth $25,231,000 after buying an additional 412,762 shares during the last quarter. Finally, Ameriprise Financial Inc. lifted its stake in shares of Personalis by 1,172.0% in the 2nd quarter. Ameriprise Financial Inc. now owns 329,865 shares of the company’s stock worth $2,164,000 after acquiring an additional 303,933 shares during the period. Hedge funds and other institutional investors own 61.91% of the company’s stock.

Personalis Company Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.